205 related articles for article (PubMed ID: 31820707)
21. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
Chella N; Daravath B; Kumar D; Tadikonda RR
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887
[TBL] [Abstract][Full Text] [Related]
22. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Isavuconazonium Sulfate.
Plano D; Rudolph N; Saal C; Abrahamsson B; Cristofoletti R; Kambayashi A; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Charoo N; Dressman J
J Pharm Sci; 2024 Feb; 113(2):386-395. PubMed ID: 37951471
[TBL] [Abstract][Full Text] [Related]
23. Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate.
Charoo NA; Shamsher AA; Lian LY; Abrahamsson B; Cristofoletti R; Groot DW; Kopp S; Langguth P; Polli J; Shah VP; Dressman J
J Pharm Sci; 2014 Feb; 103(2):378-91. PubMed ID: 24382794
[TBL] [Abstract][Full Text] [Related]
24. Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs.
Li Z; Zhang W; Gao Y; Xiang R; Liu Y; Hu M; Zhou M; Liu X; Wang Y; He Z; Sun Y; Sun J
Drug Deliv Transl Res; 2017 Feb; 7(1):100-110. PubMed ID: 27812915
[TBL] [Abstract][Full Text] [Related]
25. Biowaiver or Bioequivalence: Ambiguity in Sildenafil Citrate BCS Classification.
Miranda C; Pérez-Rodríguez Z; Hernández-Armengol R; Quiñones-García Y; Betancourt-Purón T; Cabrera-Pérez MÁ
AAPS PharmSciTech; 2018 May; 19(4):1693-1698. PubMed ID: 29532425
[TBL] [Abstract][Full Text] [Related]
26. Study on biopharmaceutics classification and oral bioavailability of a novel multikinase inhibitor NCE for cancer therapy.
Yang Y; Fan CM; He X; Ren K; Zhang JK; He YJ; Yu LT; Zhao YL; Gong CY; Zheng Y; Song XR; Zeng J
Int J Mol Sci; 2014 Apr; 15(5):7199-212. PubMed ID: 24776763
[TBL] [Abstract][Full Text] [Related]
27. Donepezil Hydrochloride BCS Class Ambiguity: Relevant Aspects to be Considered in Drug Classification.
de Campos DP; Silva-Barcellos NM; Caldeira TG; Mussel WDN; Silveira V; de Souza J
J Pharm Sci; 2022 Nov; 111(11):3064-3074. PubMed ID: 35787368
[TBL] [Abstract][Full Text] [Related]
28. Dissolution of a Biopharmaceutics Classification System Class II Free Acid from Immediate Release Tablets Containing a Microenvironmental pH Modulator: Comparison of a Biorelevant Bicarbonate Buffering System with Phosphate Buffers.
Haznar-Garbacz D; Hoc D; Garbacz G; Lachman M; Słomińska D; Romański M
AAPS PharmSciTech; 2022 Jul; 23(6):203. PubMed ID: 35882674
[TBL] [Abstract][Full Text] [Related]
29. Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives.
Breda SA; Jimenez-Kairuz AF; Manzo RH; Olivera ME
Int J Pharm; 2009 Apr; 371(1-2):106-13. PubMed ID: 19150493
[TBL] [Abstract][Full Text] [Related]
30. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
[TBL] [Abstract][Full Text] [Related]
31. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
32. Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs.
Ono A; Kurihara R; Terada K; Sugano K
Chem Pharm Bull (Tokyo); 2023; 71(3):213-219. PubMed ID: 36858526
[TBL] [Abstract][Full Text] [Related]
33. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
34. Biopharmaceutics classification of puerarin and comparison of perfusion approaches in rats.
Li H; Dong L; Liu Y; Wang G; Wang G; Qiao Y
Int J Pharm; 2014 May; 466(1-2):133-8. PubMed ID: 24607203
[TBL] [Abstract][Full Text] [Related]
35. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
Biswas N
Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
[TBL] [Abstract][Full Text] [Related]
36. In Vitro and In Situ Characterization of Triterpene Glycosides From Cimicifuga racemosa Extract.
Disch L; Forsch K; Siewert B; Drewe J; Fricker G
J Pharm Sci; 2017 Dec; 106(12):3642-3650. PubMed ID: 28827038
[TBL] [Abstract][Full Text] [Related]
37. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.
Plöger GF; Quizon PM; Abrahamsson B; Cristofoletti R; Groot DW; Parr A; Langguth P; Polli JE; Shah VP; Tajiri T; Mehta MU; Dressman J
J Pharm Sci; 2020 Jun; 109(6):1846-1862. PubMed ID: 32240696
[TBL] [Abstract][Full Text] [Related]
38. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
39. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion.
Park YJ; Lee HK; Im YB; Lee W; Han HK
Arch Pharm Res; 2010 Aug; 33(8):1235-40. PubMed ID: 20803127
[TBL] [Abstract][Full Text] [Related]
40. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
